Results (3967)
Observational Study of Pregnancy and Infant Outcomes Among Women Exposed to Mirikizumab During Pregnancy in US-based Administrative Claims Data (I6T-MC-B003)
United States
EU PAS number:
EUPAS105674
First published:
17/05/2024
StudyPlanned
Mirikizumab Pregnancy Registry (I6T-MC-B006)
United States
EU PAS number:
EUPAS107688
First published:
17/05/2024
StudyPlanned
Depicting real-life treatment journeys for patients affected with an immune-inflammatory condition and treated with methotrexate
France
EU PAS number:
EUPAS1000000159
First published:
17/05/2024
StudyOngoing
A Prospective, Multicentre, Non-interventional, Observational, Post-authorisation Safety Study of Ropeginterferon alfa-2b in Polycythaemia Vera Patients (Besremi-PASS)
Austria
Germany
Romania
EU PAS number:
EUPAS29462
First published:
17/05/2024
StudyOngoing
Zanamivir 10mg/ml solution for infusion pregnancy registry: an observational study of the safety of zanamivir 10mg/ml solution for infusion exposure in pregnant women with complicated influenza and their offspring (208140)
United Kingdom
EU PAS number:
EUPAS33189
First published:
17/05/2024
StudyPlanned
Safety profile of Tiotropium + Olodaterol used as maintenance treatment in COPD patients in Taiwan: a non-interventional study based on the Taiwan National Health Insurance (NHI) data (1237-0109)
China
EU PAS number:
EUPAS47368
First published:
17/05/2024
StudyFinalised
Prospective International Observational Cohort Study Assessing Safety Outcomes Among Squamous Non-small Cell Lung Cancer Patients Treated with Necitumumab in Combination with Gemcitabine and Cisplatin in Comparison to Patients Treated with Cisplatin-based Doublets (I4X-MC-B002)
Austria
Germany
EU PAS number:
EUPAS12595
First published:
17/05/2024
StudyFinalised
Baricitinib Drug Utilisation Study: Assessment of Effectiveness of New Recommendations for Use Based on Secondary Data Sources in France, Germany, The Netherlands, and Sweden (I4V-MC-B038)
France
Germany
Netherlands
Sweden
EU PAS number:
EUPAS104431
First published:
17/05/2024
StudyPlanned
Test-and-treat Helicobacter pylori for gastric cancer prevention
Croatia
Ireland
Latvia
Poland
Romania
Slovenia
EU PAS number:
EUPAS1000000144
First published:
17/05/2024
StudyOngoing
Ospedale Bambino Gesù Pediatric Oncology Health Data database
Italy
Poland
Romania
Ukraine
First published:
17/05/2024
Data source
BiobankHospital inpatient recordsHospital outpatient visit recordsSpecialist ambulatory care recordsProspective Study to Assess Usage, Adherence, Effectiveness of Cabotegravir LA for Pre-Exposure Prophylaxis in the United States in the OPERA Cohort (219844)
United States
EU PAS number:
EUPAS1000000165
First published:
17/05/2024
StudyOngoing
Health Research Institute of the Balearic Islands
Spain
First published:
17/05/2024
Data source
Hospital inpatient recordsPharmacy dispensing recordsPrimary care medical recordsMorquio A Registry Study (MARS)
Australia
Austria
Belgium
Canada
Czechia
Denmark
France
Ireland
Italy
Malaysia
Netherlands
Poland
Portugal
Puerto Rico
Taiwan
United Kingdom
United States
EU PAS number:
EUPAS6835
First published:
17/05/2024
StudyOngoing
Impact of EU label changes for hydroxyzine products: post-referral prescribing trends
Denmark
Netherlands
United Kingdom
EU PAS number:
EUPAS26363
First published:
17/05/2024
StudyFinalised
Impact of EU label changes for systemic diclofenac products: post-referral prescribing trends
Denmark
Netherlands
United Kingdom
EU PAS number:
EUPAS24089
First published:
17/05/2024
StudyFinalised
Bendroflumethiazide versus Indapamide for Primary Hypertension: Observational (BISON) study within CPRD
United Kingdom
EU PAS number:
EUPAS25523
First published:
17/05/2024
StudyOngoing
SARS-CoV-2 VACCINATION for COVID-19 DISEASE SAFETY STUDY (VAC4COVID STUDY)
United Kingdom
EU PAS number:
EUPAS44124
First published:
17/05/2024
StudyOngoing
MEMO Research, University of Dundee
United Kingdom (Northern Ireland)
First published:
17/05/2024
Institution
Educational InstitutionNot-for-profitENCePP partnerNon-interventional Post-Authorisation Safety Study of Burosumab in the Treatment of Children >1 year of age, Adolescents and Adults with X-Linked Hypophosphataemia (XLH PASS)
Austria
Belgium
Bulgaria
Czechia
Denmark
France
Germany
Hungary
Ireland
Israel
Italy
Latvia
Netherlands
Norway
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Switzerland
United Kingdom
United Kingdom (Northern Ireland)
EU PAS number:
EUPAS32190
First published:
17/05/2024
StudyOngoing
A Non-interventional Post Authorisation Safety Study (PASS) of Patients with MoCD Type A Treated with NULIBRY (fosdenopterin)
European Union
United Kingdom
EU PAS number:
EUPAS1000000093
First published:
17/05/2024
StudyPlanned
Persistence and adherence to novel systemic pharmacological treatment of moderate to severe psoriasis vulgaris and psoriatic arthritis – A register-based cohort study in Finland and Sweden
Finland
Sweden
EU PAS number:
EUPAS28564
First published:
16/05/2024
StudyOngoing
DARWIN EU® Effectiveness of COVID-19 vaccines on severe COVID-19 and post acute outcomes of SARS-CoV-2 infection
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS107615
First published:
16/05/2024
StudyOngoing
DARWIN EU® - Chondrosarcoma: patient demographics, treatments, and survival in the period 2010-2023
Finland
France
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000162
First published:
16/05/2024
StudyPlanned
Integrated environmental and Integrated environmental and clinical surveillance for the prevention of acute respiratory infections (ARIs) in closed settings and vulnerable communities (Stell-ARI)
Italy
EU PAS number:
EUPAS106190
First published:
16/05/2024
StudyOngoing
A two-stage, prospective observational study describing the use and effectiveness of XGEVA®/ANJIAWEI® for the prevention of skeletal related events in patients with bone metastases from solid tumors relative to ZOMETA® in the People's Republic of China (20190036)
China
EU PAS number:
EUPAS104114
First published:
16/05/2024
StudyOngoing
A Real-world, Prospective, Observational Study of Prolia® (20180401)
China
EU PAS number:
EUPAS37579
First published:
16/05/2024
StudyOngoing
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers (20130193)
Austria
Finland
Norway
Sweden
United States
EU PAS number:
EUPAS15128
First published:
16/05/2024
StudyOngoing
Pharmacovigilance In Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents And/Or Methotrexate. A Pediatric Rheumatology International Trials Organisation (PRINTO)/Pediatric Rheumatology European Society (PRES) Registry (Pharmachild JIA registry)
Albania
Argentina
Australia
Austria
Belgium
Bosnia and Herzegovina
Brazil
Bulgaria
Chile
China
Colombia
Costa Rica
Croatia
Denmark
Egypt
El Salvador
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
India
Iraq
Israel
Italy
Latvia
Libyan Arab Jamahiriya
Lithuania
Mexico
Montenegro
Netherlands
New Zealand
Norway
Oman
Paraguay
Peru
Poland
Portugal
Romania
Russian Federation
Saudi Arabia
Serbia
Slovakia
Slovenia
South Africa
Spain
Sweden
Switzerland
Türkiye
United Arab Emirates
United Kingdom
Venezuela, Bolivarian Republic of
EU PAS number:
EUPAS1974
First published:
15/05/2024
StudyOngoing
PHARMACOVIGILANCE IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS (PHARMACHILD) TREATED WITH BIOLOGIC AGENTS AND/OR METHOTREXATE.
Italy
First published:
15/05/2024
Data source
Disease registryOtherModerna mRNA-1273 Observational Pregnancy Outcome Study (COVID-19)
Canada
United States
EU PAS number:
EUPAS41463
First published:
15/05/2024
StudyOngoing
mRNA-1273-P920, Post-marketing safety of elasomeran/davesomeran and andusomeran vaccines in the United States
United States
EU PAS number:
EUPAS106694
First published:
15/05/2024
StudyOngoing
mRNA-1273-P911: Long-term Outcomes of Myocarditis Following Administration of SPIKEVAX (COVID-19 Vaccine mRNA)
United States
EU PAS number:
EUPAS107256
First published:
15/05/2024
StudyOngoing
Post-Marketing Safety of SARS-CoV-2 mRNA-1273 Vaccine in the US: Active Surveillance, Signal Refinement and Self-Controlled Risk Interval (SCRI) Signal Evaluation in HealthVerity (COVID-19)
Canada
Finland
Germany
Italy
United States
EU PAS number:
EUPAS41392
First published:
15/05/2024
StudyOngoing
Auria Clinical Informatics
Finland
First published:
15/05/2024
Data source
BiobankHospital inpatient recordsOtherTelotron - Telomera
Spain
First published:
15/05/2024
Data source
Disease registryOtherPharmacy dispensing recordsPrimary care medical recordsA multicenter evaluation of the treatment persistence of advanced therapies (Biological disease-modifying agents and Targeted synthetic Disease Modifying Anti-Rheumatic Drugs) in the treatment of rheumatoid arthritis (RA): A Real World Evidence (RWE) study from India
India
EU PAS number:
EUPAS103727
First published:
15/05/2024
StudyPlanned
An Immuno-Dermatological disease registry to understand the burden of Atopic dermatitis (AD), Alopecia areata (AA), and Vitiligo in Indian Patients
India
EU PAS number:
EUPAS48566
First published:
15/05/2024
StudyOngoing
A Longitudinal, Retrospective, Multi-centre Observational Study to Evaluate Effectiveness, Persistence, Treatment Patterns and Safety of Australian Patients Receiving Early Access to Tofacitinib
Australia
EU PAS number:
EUPAS41439
First published:
15/05/2024
StudyOngoing
Safety and Effectiveness of MVA-BN vaccination against MPXV infection in at-risk individuals in Germany (SEMVAc) (DRKS ID: DRKS00029638 (SEMVAc))
Germany
EU PAS number:
EUPAS50093
First published:
15/05/2024
StudyPlanned
A multicentre observational, prospective cohort study including patients with acute coronary syndromes undergoing percutaneous coronary intervention who receive cangrelor i.v. transitioning to either clopidogrel, prasugrel or ticagrelor per os (ARCANGELO)
Italy
EU PAS number:
EUPAS36393
First published:
15/05/2024
StudyOngoing